Business Wire Feed

Pulse Biosciences to Host Analyst Event on April 25, 2026

April 17th, 2026|

Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter SystemHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced more...

Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors

April 16th, 2026|

Acerand Therapeutics Reports Promising Clinical Activity and Favorable Safety Profile for ACE-106, a Potential Best-in-Class PARP1 Selective InhibitorSHANGHAI & INDIANAPOLIS--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, metabolic diseases, more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.